Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles:
Related suggestion:
At least 70 people killed by flooding in Kenya as more rain is expected through the weekendRelegationFemale California teacher, 46, pleads no contest to raping 14 yearA California bill aiming to ban confidentiality agreements when negotiating legislation failsPEN America cancels World Voices Festival amid criticism of its response to IsraelPEN America cancels World Voices Festival amid criticism of its response to IsraelRelegationJournalists sign manifesto in defense of Spanish PM and wife, criticize rightJudge upholds disqualification of challenger to judge in Trump’s Georgia election interference caseI have £300,000 invested in a pension
2.6998s , 6516.546875 kb
Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,Universal Update news portal